Lipella Pharmaceuticals Inc.

Equities

LIPO

US53630L1008

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 04:00:44 2024-04-30 pm EDT			5-day change	1st Jan Change
0.716 ^USD	-1.24%		+1.75%	-28.57%

Apr. 17	Lipella Pharmaceuticals Inc. Appoints Jason Hafron and Pradeep Tyagi to Scientific Advisory Board	CI
Apr. 09	Maxim Initiates Lipella Pharmaceuticals at Buy Rating With $2 Price Target	MT

Lipella Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023

August 14, 2023 at 04:05 pm EDT

Lipella Pharmaceuticals Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported revenue was USD 0.106676 million. Net loss was USD 1.54 million compared to USD 0.782024 million a year ago. Basic loss per share from continuing operations was USD 0.27 compared to USD 0.2 a year ago. Diluted loss per share from continuing operations was USD 0.27 compared to USD 0.2 a year ago.
For the six months, revenue was USD 0.224724 million compared to USD 0.033149 million a year ago. Net loss was USD 2.61 million compared to USD 1.52 million a year ago. Basic loss per share from continuing operations was USD 0.45 compared to USD 0.39 a year ago. Diluted loss per share from continuing operations was USD 0.45 compared to USD 0.39 a year ago.

Latest news about Lipella Pharmaceuticals Inc.

Lipella Pharmaceuticals Inc. Appoints Jason Hafron and Pradeep Tyagi to Scientific Advisory Board	Apr. 17	CI
Maxim Initiates Lipella Pharmaceuticals at Buy Rating With $2 Price Target	Apr. 09	MT
Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-410 for Oral Graft-Versus-Host Disease, Advancing Clinical Pipeline	Mar. 05	CI
Lipella Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27	CI
Wall Street Set to Open Lower Friday; Employment Growth Tops Forecasts	Dec. 08	MT
Top Premarket Decliners	Dec. 08	MT
Lipella Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Lipella Gets FDA Orphan Designation for LP-310 in Oral Graft-vs-Host Disease	Nov. 10	DJ
Lipella Pharmaceuticals Inc. announced that it has received $1.998685 million in funding	23-10-24	CI
Lipella Pharmaceuticals Inc. announced that it expects to receive $1.998685 million in funding	23-10-23	CI
Sector Update: Health Care Stocks Softer Late Afternoon	23-10-20	MT
Top Midday Gainers	23-10-20	MT
Sector Update: Health Care Stocks Slightly Higher Friday Afternoon	23-10-20	MT
Sector Update: Health Care	23-10-20	MT
Lipella Pharmaceuticals Says US FDA Approves IND Status for LP-310 for Oral Lichen Planus; Shares Surge	23-10-20	MT
Investors Remain Cautious Over Fed Moves, Setting Wall Street Up for Lower Open	23-10-20	MT
Lipella Pharmaceuticals Inc. Announces FDA Clearance of IND for LP-310 for Oral Lichen Planus	23-10-20	CI
Lipella Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Lipella Pharmaceuticals Inc. announced a financing transaction	23-07-09	CI
Lipella Pharmaceuticals Inc. Appoints Lori Birder as a Member of the Board	23-06-23	CI
Certain Options of Lipella Pharmaceuticals Inc. are subject to a Lock-Up Agreement Ending on 17-JUN-2023.	23-06-16	CI
Certain Warrants of Lipella Pharmaceuticals Inc. are subject to a Lock-Up Agreement Ending on 17-JUN-2023.	23-06-16	CI
Certain Preferred Stock of Lipella Pharmaceuticals Inc. are subject to a Lock-Up Agreement Ending on 17-JUN-2023.	23-06-16	CI
Certain Common Stock of Lipella Pharmaceuticals Inc. are subject to a Lock-Up Agreement Ending on 17-JUN-2023.	23-06-16	CI
Lipella Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI

Chart Lipella Pharmaceuticals Inc.

Duration

Period

More charts

Company Profile

Lipella Pharmaceuticals Inc. is a clinical-stage biotechnology company. It is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. Its lead product candidates include LP-10, LP-310 and LP-410. LP-10 is the development name of its reformulation of tacrolimus specifically optimized for topical deposition to the internal surface of the urinary bladder lumen using a proprietary drug delivery platform. LP-310 is the development name of its oral, liposomal formulation of tacrolimus specifically optimized for local delivery to oral mucosa. It is also developing an oral, liposomal formulation of tacrolimus, LP-410, for the treatment of oral graft-versus-host disease (GVHD). LP-410 is an oral rinse, like LP-310, but has a different containment system. LP-410 targets the underlying mechanisms of oral GVHD, potentially providing a safe and effective treatment option for affected individuals.

Sector

Biotechnology & Medical Research

Calendar

2024-05-30 - American Society of Clinical Oncology Annual Meeting

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.725 USD

Average target price

2 USD

Spread / Average Target

+175.86%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
LIPELLA PHARMACEUTICALS INC.	-28.57%	5.1M
VERTEX PHARMACEUTICALS INCORPORATED	-3.14%	102B
REGENERON PHARMACEUTICALS, INC.	+1.65%	96.29B
ARGENX SE	+2.13%	22.18B
BIONTECH SE	-15.69%	21.2B
GENMAB A/S	-9.21%	18.31B
WUXI APPTEC CO., LTD.	-39.98%	17.38B
BEIGENE, LTD.	-14.28%	16.36B
NEUROCRINE BIOSCIENCES, INC.	+4.76%	13.97B
SAREPTA THERAPEUTICS, INC.	+32.22%	12.17B

Bio Therapeutic Drugs